Allium CE marks prostatic stent
This article was originally published in Clinica
Allium Group has CE marked its prostatic stent for sale in Europe. Used in patients with benign prostatic hyperplasia (BPH) or with advanced prostate cancer, the device has a triangular cross-section to match the contours of the prostatic urethra, and can exert varying degrees of radial force depending on the anatomy and function of the part of the urethra in which it is deployed. This means the device is more comfortable than existing stents in the long term, the Caesarea, Israel firm said. Distribution of the stent will begin during the first months of 2009.